EVast Bio develops small Extracellular Vesicles (sEVs) as nanotherapeutics and targeted delivery systems for clinical applications. These nano-vehicles precisely deliver therapeutic cargo, including native molecules or drugs, to specific sites within the body. The company leverages the unique properties of sEVs to enhance the safety and efficacy of drug delivery.
Funding
Funding not disclosed
Founders
Product
Problem
Targeted drug delivery to specific tissues remains a challenge, limiting the efficacy and increasing the systemic toxicity of many therapeutics. Traditional drug delivery methods often lack the precision needed to reach the intended site of action, resulting in off-target effects and suboptimal treatment outcomes. This is particularly problematic in diseases like osteoarthritis and prostate cancer, where localized treatment is crucial.
Solution
This startup is developing a clinical-stage platform leveraging extracellular vesicles (EVs) for targeted drug delivery. The platform focuses on utilizing EVs to deliver microRNA and proteins directly to diseased cells and tissues. By engineering EVs to selectively target specific cells, the technology aims to enhance treatment efficacy while minimizing off-target effects. This approach offers a more precise and effective therapeutic option for conditions like osteoarthritis and prostate cancer, potentially improving patient outcomes and reducing adverse reactions.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing targeted therapies for diseases such as osteoarthritis and prostate cancer.
Features
- Engineered extracellular vesicles for targeted delivery of therapeutic payloads
- Customizable EV surface modifications for enhanced cell-specific targeting
- Optimized loading methods for efficient encapsulation of microRNA and proteins
- Scalable manufacturing process for clinical-grade EV production
- In vivo validation studies demonstrating improved drug delivery and efficacy